# Investigating Efficacy and Safety of JETi® in Arterial Occlusions in FEM-POP and Prox BTK-Lesions (JETART)

Study · id `cardio:ct-nct06434779` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06434779](<https://clinicaltrials.gov/study/NCT06434779>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06434779

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06434779. Allocation not applicable; no masking; primary purpose treatment. Start 2024-07 (anticipated); primary completion 2026-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06434779, source copy `cardio:ctgov-nct06434779-2024-07-16`, retrieved 2026-10-31)
- Planned start: 2024-07 (anticipated) (ClinicalTrials.gov record NCT06434779, source copy `cardio:ctgov-nct06434779-2024-07-16`, retrieved 2026-10-31)
- Primary completion: 2026-05 (anticipated) (ClinicalTrials.gov record NCT06434779, source copy `cardio:ctgov-nct06434779-2024-07-16`, retrieved 2026-10-31)
- Completion: 2026-05 (anticipated) (ClinicalTrials.gov record NCT06434779, source copy `cardio:ctgov-nct06434779-2024-07-16`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06434779-2024-07-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Investigating Efficacy and Safety of JETi® in Arterial Occlusions in FEM-POP and Prox BTK-Lesions (JETART)
- Acronym: JETART
- Condition: Peripheral Arterial Disease
- Intervention (Device): JETi 6F and 8F Thrombectomy system
- Lead sponsor: Vascular Science LP GmbH
- Lead sponsor class: OTHER
- Collaborator: ID3 Medical
- Collaborator class: OTHER
- Collaborator: Abbott
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as a collaborator: ID3 Medical (`cardio:org-id3-medical`)
- Registry lists this organization as a collaborator: Abbott (`cardio:abbott`)

## Provenance

Content hash: f126cc4c5f5d63785fdd9a179f66acd58fcd6a0d310f86b4d9fc890f15346600
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
